NASDAQ:AFMD - Affimed Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.35 +0.10 (+2.35 %) (As of 09/19/2018 02:55 AM ET)Previous Close$4.25Today's Range$4.20 - $4.4552-Week Range$1.15 - $7.35Volume736,800 shsAverage Volume1.06 million shsMarket Capitalization$283.88 millionP/E Ratio-5.58Dividend YieldN/ABeta3.42 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, a NK-cell bispecific antibody targets EGFR-wild type represents a validated antigen expressed by various solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany. Receive AFMD News and Ratings via Email Sign-up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:AFMD CUSIPN/A Webwww.affimed.com Phone49-62-2165-3070 Debt Debt-to-Equity Ratio0.06 Current Ratio5.36 Quick Ratio5.33 Price-To-Earnings Trailing P/E Ratio-5.58 Forward P/E Ratio-6.90 P/E GrowthN/A Sales & Book Value Annual Sales$2.27 million Price / Sales119.56 Cash FlowN/A Price / CashN/A Book Value$0.80 per share Price / Book5.44 Profitability EPS (Most Recent Fiscal Year)($0.78) Net Income$-34,160,000.00 Net Margins-1,723.04% Return on Equity-74.04% Return on Assets-57.62% Miscellaneous Employees8,406 Outstanding Shares62,390,000Market Cap$283.88 million Affimed (NASDAQ:AFMD) Frequently Asked Questions What is Affimed's stock symbol? Affimed trades on the NASDAQ under the ticker symbol "AFMD." How were Affimed's earnings last quarter? Affimed NV (NASDAQ:AFMD) posted its quarterly earnings data on Wednesday, August, 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.01. The biopharmaceutical company earned $0.18 million during the quarter, compared to analysts' expectations of $0.61 million. Affimed had a negative return on equity of 74.04% and a negative net margin of 1,723.04%. View Affimed's Earnings History. When is Affimed's next earnings date? Affimed is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Affimed. What price target have analysts set for AFMD? 3 brokerages have issued 12-month price targets for Affimed's shares. Their predictions range from $4.00 to $5.00. On average, they anticipate Affimed's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price. View Analyst Price Targets for Affimed. What is the consensus analysts' recommendation for Affimed? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Affimed. Who are some of Affimed's key competitors? Some companies that are related to Affimed include Karyopharm Therapeutics (KPTI), Athenex (ATNX), Dicerna Pharmaceuticals (DRNA), Zai Lab (ZLAB), Vanda Pharmaceuticals (VNDA), Apellis Pharmaceuticals (APLS), Rhythm Pharmaceuticals (RYTM), Aptinyx (APTX), Eagle Pharmaceuticals (EGRX), Geron (GERN), MacroGenics (MGNX), Rocket Pharmaceuticals (RCKT), Revance Therapeutics (RVNC), TG Therapeutics (TGTX) and Assembly Biosciences (ASMB). Who are Affimed's key executives? Affimed's management team includes the folowing people: Dr. Adi Hoess M.D., Ph.D., CEO, MD & Member of Management Board (Age 56)Dr. Florian H. M. Fischer MBA (Dipl.-Kfm.), Ph.D., MD, CFO & Member of Management Board (Age 50)Prof. Melvyn Little, Founder & ConsultantDr. Wolfgang Fischer, Chief Operating OfficerDr. Martin Treder, Chief Scientific Officer (Age 48) Has Affimed been receiving favorable news coverage? Press coverage about AFMD stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Affimed earned a news impact score of 0.18 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Affimed. Who are Affimed's major shareholders? Affimed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.87%), Renaissance Technologies LLC (0.28%), Canada Pension Plan Investment Board (0.16%) and Stanley Laman Group Ltd. (0.10%). Which institutional investors are selling Affimed stock? AFMD stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. Which institutional investors are buying Affimed stock? AFMD stock was purchased by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Stanley Laman Group Ltd. and Renaissance Technologies LLC. How do I buy shares of Affimed? Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Affimed's stock price today? One share of AFMD stock can currently be purchased for approximately $4.35. How big of a company is Affimed? Affimed has a market capitalization of $283.88 million and generates $2.27 million in revenue each year. The biopharmaceutical company earns $-34,160,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. Affimed employs 8,406 workers across the globe. How can I contact Affimed? Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2165-3070 or via email at [email protected] MarketBeat Community Rating for Affimed (NASDAQ AFMD)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 178 (Vote Outperform)Underperform Votes: 195 (Vote Underperform)Total Votes: 373MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote "Outperform" if you believe AFMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/19/2018 by MarketBeat.com StaffFeatured Article: What is the NASDAQ?